TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01864590

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vacuum Pack
Description: Vacuum Pack Technique described by Barker et al.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Double Sylo Bag - Mesh Protocol
Description: double sylo bag, one underneath the fascia and the other sutured to the skin, at the initial operation.~At subsequent surgeries once the abdomen is clean the investigators leave the same subfascial sylo bag and use a prolene mesh attached to the fascia. This mesh is resutured every day until the abdominal fascia is approximated enough to permit closure
Study: NCT01141985

Intervention type: DEVICE
Group type: OTHER
Intervention: LenSx Laser modified disposable contact lens
Description: Modified Disposable Contact Lens Patient Interface: Like the current disposable contact lens, a single unit is used for each procedure only once, and is then discarded. It is similarly mounted onto the distal end of the system's focusing objective and serves as a sterile barrier between the patient and the laser. In place of a separate suction ring that is used in the current contact lens, the modified contact lens has an integrated suction ring and curved applanation surface. These features result in significantly lower elevation of intraocular pressure and significantly easier application by the surgeon in preliminary testing. Identical to the current contact lens, the suction ring is applied around the patient's limbus and mild suction is applied to stabilize the eye.
Study: NCT03927963

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine 0.7 ug/kg/h with sevoflurane 0.5 MAC and remifentanil infusion are used throughout anesthesia period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: Effect site concentration of propofol 1.5 ng/ml with sevoflurane 0.5 MAC and remifentanil infusion are used throughout anesthesia period
Study: NCT00801528

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine, Diclofenac, Water for injection
Description: Ropivacaine 0.2 %, or diclofenac (300 mg/240 ml water for injection) or water for injection will be administered as a constant instillation rate set of 10 mL/hr for the subsequent 18 postoperative hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine, Diclofenac, Water for injection
Description: Ropivacaine 0.2 %, or diclofenac (300 mg/240 ml water for injection) or water for injection will be administered as a constant instillation rate set of 10 mL/hr for the subsequent 18 postoperative hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine, Diclofenac, Water for injection
Description: Ropivacaine 0.2 %, or diclofenac (300 mg/240 ml water for injection) or water for injection will be administered as a constant instillation rate set of 10 mL/hr for the subsequent 18 postoperative hours.
Study: NCT00499603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500 mg/m\^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500 mg/m\^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: 30 mg by mouth weekly on Days 1, 8, \& 15 for 12 cycles.
Study: NCT05660694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Description: Comparison of Triamcinolone with Pentoxifylline and Vitamin- E Efficacy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline with Vitamin E
Description: Comparison of Triamcinolone with Pentoxifylline and Vitamin- E Efficacy
Study: NCT04720521

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: OE+white light
Description: Firstly use white light to observe from esophagus to duodenum and then switch OE mode to observe from antrum to esophagus
Study: NCT01985750

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: d-cycloserine
Description: 250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Other Names:~comparison of d-cycloserine or placebo on enhancing the beneficial effects of pulmonary rehabilitation on breathlessness perception~250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation
Study: NCT00526591

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Patients will receive arm-specific dosage of Everolimus daily continuously for 8 week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Patients will receive arm-specific dosage of Everolimus daily continuously for 8 week

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery
Description: Radical prostatectomy with bilateral pelvic lymphadenectomy will be performed within 10 days of the completion of week 8 on RAD-001 (Everolimus).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: Radical prostatectomy with bilateral pelvic lymphadenectomy will be performed within 10 days of the completion of week 8 on RAD-001 (Everolimus).
Study: NCT01062152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezatiostat Hydrochloride
Description: Starting dose 2000 mg orally in divided doses twice daily (1000 mg in AM \& 1000 mg in PM) x 21 days with one week off therapy in a 4-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide (Revlimid®)
Description: 10 mg orally per day in one AM dose x 21 days with one week off therapy in a 4-week cycle.
Study: NCT04947241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor+ Gemcitabine + Cisplatin
Description: Before surgery, patients will receive therapy as follows:~PD-1 inhibitor: 240mg (day1) , intravenous, Q3W, 2cycles; cisplatin: 80 mg/m2(day1), intravenous , intravenous, Q3W, 2cycles Gemcitabine: 1000mg/m2(day1and day8), intravenous, Q3W, 2cycles
Study: NCT01057186

Intervention type: DIETARY_SUPPLEMENT
Intervention: Alfacalcidol; phosphate.
Description: Individual dosage form and dosage depending on phenotype and underlying cause.

Intervention type: DRUG
Intervention: Sevelamer
Description: Pills. Individual dosage depending on clinical symptoms/phenotype.
Study: NCT01441804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa2a
Description: patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon alfa2a
Description: patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks
Study: NCT00116220

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flutamide (Eulexin) and Lupron or Zoladex
Description: Androgen suppression therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External Beam Radiotherapy
Description: Once a day, 4-5 days per week for approximately 2 months

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External Beam Radiotherapy
Description: Once a day, 4-5 days per week for approximately 2 months
Study: NCT01731366

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole grain
Description: Whole grain diet: Participants consume more than 75g of whole grain per day (corresponds to the whole grain intake of the 90th percentile of the population)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Refined grain
Description: Refined grain diet: Participants consume less than 10 g of whole grain per day (corresponds to the whole grain intake below the 10th percentile of the population)
Study: NCT04273893

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT with additional treatment planning dose optimization
Description: Lung SBRT 50-60Gy in 5 fractions with standard of care planning and additional treatment planning dose optimization criteria to minimize decrease in lymphocyte count beyond dosimetric criteria from RTOG 0915/0813 SBRT trials.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: SBRT with standard of care planning only
Description: Lung SBRT 50-60Gy in 5 fractions with standard of care planning (no additional dose optimization beyond SOC)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood Draws
Description: CBC w/ Diff and additional blood analysis for all participants in both groups. Blood draws will prior to treatment, end of treatment, 4 weeks after treatment, and 6 months after treatment.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood Draws
Description: CBC w/ Diff and additional blood analysis for all participants in both groups. Blood draws will prior to treatment, end of treatment, 4 weeks after treatment, and 6 months after treatment.
Study: NCT02588261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naquotinib mesilate
Description: Participants received ASP8273 300 mg orally once daily on an empty stomach (no food for at least 2 hours before and 1 hour after taking drug) at approximately the same time every day.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: Participants received erlotinib 150 mg orally once daily on an empty stomach (no food for at least 2 hours before and 1 hour after taking drug) at approximately the same time every day. At the beginning of the trial, prior to site initiation and shipment of study drug supplies, each investigator selected either erlotinib or gefitinib to be utilized for all participants randomized to the comparator arm at their site.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gefitinib
Description: Participants received gefitinib 250 mg was taken orally once daily with water, with or without food, at approximately the same time every day. At the beginning of the trial, prior to site initiation and shipment of study drug supplies, each investigator selected either erlotinib or gefitinib to be utilized for all participants randomized to the comparator arm at their site.
Study: NCT01898429

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SCC DBS
Description: Deep Brain Stimulator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SCC DBS
Description: Deep Brain Stimulator
Study: NCT03653143

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: JASPER
Description: JASPER is a therapist and parent-mediated intervention that (1) targets the foundations of social communication, (2) uses naturalistic behavioral strategies to increase the rate and complexity of social communication and (3) includes parents as implementers of the intervention to promote generalization across settings and to ensure maintenance. This intervention is individualized and centered around two key developmental domains critical for social communication function: joint engagement and joint attention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: JASPER
Description: JASPER is a therapist and parent-mediated intervention that (1) targets the foundations of social communication, (2) uses naturalistic behavioral strategies to increase the rate and complexity of social communication and (3) includes parents as implementers of the intervention to promote generalization across settings and to ensure maintenance. This intervention is individualized and centered around two key developmental domains critical for social communication function: joint engagement and joint attention.
Study: NCT01035619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: moxidectin
Description: Single Dose Moxidectin 4 mg
Study: NCT03325842

Intervention type: DIAGNOSTIC_TEST
Intervention: ASKp
Description: 30 items questionnaire

Intervention type: DIAGNOSTIC_TEST
Intervention: ASKp
Description: 30 items questionnaire
Study: NCT02287467

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravenous hyperimmune immunoglobulin (IVIG)
Description: Administered intravenously (IV) at a dose of 0.25 g/kg (up to a maximum of 24.75 g, corresponding to approximately 100 kg actual body weight)

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for IVIG
Description: Administered IV as 500 mL of normal saline
Study: NCT03020706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate, Injectable
Description: magnesium sulphate intravenous administration during general anesthesia
Study: NCT00255788

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: everolimus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: everolimus
Study: NCT03106636

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: KEEP-P
Description: The KEEP-P program is a low-cost, manualized, group-based intervention for caregivers of preschool aged children. This trial is evaluating 2 versions of the intervention. KEEP-P is a basic version that employs a curriculum of 12 weekly psychoeducational caregiver support groups Across four waves of data collection (baseline, post-intervention, and 12 and 18 months post-baseline), we will examine the extent to which this intervention condition shows improved parenting, reduced rates of disrupted placements, and improved child outcomes.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KEEP-P+
Description: The KEEP-P program is a low-cost, manualized, group-based intervention for caregivers of preschool aged children. This trial is evaluating 2 versions of the intervention. KEEP-P+ is an augmented version that consists of the caregiver support groups with extended curriculum including information about recent findings in early brain development and the elements of the Filming Interactions to Nurture Development video coaching program. Across four waves of data collection (baseline, post-intervention, and 12 and 18 months post-baseline), we will examine the extent to which this intervention condition show improved parenting, reduced rates of disrupted placements, and improved child outcomes.
Study: NCT04233541

Intervention type: DIAGNOSTIC_TEST
Intervention: Fall assessment
Description: Through a comprehensive geriatric assessment carried out by our geriatrician led multidisciplinary team we gather information about fall recalls consistent with the definition of landing on the floor or ground.

Intervention type: DIAGNOSTIC_TEST
Intervention: Fall assessment
Description: Through a comprehensive geriatric assessment carried out by our geriatrician led multidisciplinary team we gather information about fall recalls consistent with the definition of landing on the floor or ground.
Study: NCT03630757

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment
Description: In the study group, a total of 15 sessions of a manual therapy program including myofascial release and mobilization techniques were applied for 60-minute session for 3 weeks(5/wk).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment
Description: In the study group, a total of 15 sessions of a manual therapy program including myofascial release and mobilization techniques were applied for 60-minute session for 3 weeks(5/wk).
Study: NCT02529176

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Best-practice alert
Description: The best-practice alert notifies physicians that their patient's telemetry monitoring duration has exceeded national guidelines and gives the physician the option to: discontinue monitoring if they feel it is clinically appropriate, dismiss the alert, or re-alert in four hours.
Study: NCT00958971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI258
Description: All participants received a singly daily oral dose of 500 mg dovitinib on a 5 days on/2 days off schedule in 28 cycles.
Study: NCT01103934

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 4000 IU once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo taken once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone Propionate
Description: 200 mcg daily, intranasal
Study: NCT01401517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium nitrite
Description: 0, 40 or 80 mg twice each day for 10 weeks followed by a 1 week escalation of 2 times the dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium nitrite
Description: 0, 40 or 80 mg twice each day for 10 weeks followed by a 1 week escalation of 2 times the dose.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sodium nitrite
Description: 0, 40 or 80 mg twice each day for 10 weeks followed by a 1 week escalation of 2 times the dose.
Study: NCT00958971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI258
Description: All participants received a singly daily oral dose of 500 mg dovitinib on a 5 days on/2 days off schedule in 28 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI258
Description: All participants received a singly daily oral dose of 500 mg dovitinib on a 5 days on/2 days off schedule in 28 cycles.
Study: NCT01766180

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fruitflow-II
Description: 150 mg/day for 3 months, orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fruitflow-II
Description: 150 mg/day for 3 months, orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: resVida
Description: 150 mg/day for 3 months, orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: resVida
Description: 150 mg/day for 3 months, orally
Study: NCT02458573

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: continuous epidural analgesia
Description: the continuous epidural analgesia group: epidural analgesia started from induction of anesthesia and continued for 48 h.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: continuous intravenous analgesia
Description: the continuous intravenous analgesia group: intravenous analgesia started from induction of anesthesia and continued for 48 h.
Study: NCT02398604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allo-hMSCs
Description: Allogeneic Human Mesenchymal Stem Cells

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02159976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: Pantoprazole 40mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: Pantoprazole 40mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Amoxicillin 1000mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Amoxicillin 1000mg bid
Study: NCT01103934

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate
Description: 200 mcg daily, intranasal
Study: NCT02159976

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Clarithromycin 500mg bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Metronidazole 500mg tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracycline
Description: Tetracycline 1000mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bismuth
Description: Bismuth 600mg bid
Study: NCT06341998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus combined with chemotherapy in the treatment of recurrent/refractory yolk sac tumor in children
Description: The oral dose of sirolimus is 1mg/m2 daily (maximum 2 mg). Sirolimus whole blood trough concentration is measured 5 days after administration, with blood collected within half an hour before morning administration. Dose adjustment occurs weekly until the target range of 10-15ng/ml is achieved, followed by review every 21 days. Each cycle lasts for 21 days (every three weeks), and if treatment parameters are met as described in the study, cycle two and subsequent cycles begin on day 22. Treatment will be discontinued if there is drug-related dose-limiting toxicity or disease progression. Tumor response assessment will be repeated using AFP and LDH every one cycle and imaging examination every two cycles. Children who complete the trial may continue this regimen or undergo surgery or radiation therapy if their disease goes into remission.
Study: NCT00668746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline HCl microspheres
Description: At Baseline and all interim visits, a single unit dose of 1mg minocycline HCl (with approximately 3mg PGLA) will be professionally administered subgingivally into periodontal pockets at each site exhibiting a PD ≥ 5mm.
Study: NCT02717780

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl and sevoflurane

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil and desflurane
Study: NCT01717625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: a leukotriene D4 receptor antagonist; sodium salt is the active compound; structure in first source
Study: NCT04184622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC
Study: NCT02759250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARGX-110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARGX-110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARGX-110